Halozyme Therapeutics Financial Ratios
NASDAQ: HALOHealth CareBiotechnology: Biological Products (No Diagnostic Substances)USD
At close: Oct 9, 4:00 PM ET · Delayed 15 min
Halozyme Therapeutics ratio analysis
Halozyme Therapeutics earned a net margin of 22.7% in FY 2025, down from 43.7% a year earlier. Gross margin was 83.6% compared with a median of 81.6% over the prior 9 years. Return on equity reached 649.2%, meaning Halozyme Therapeutics generated 6.49 dollars of profit for every dollar of shareholders' equity, an unusually high figure that often reflects a small equity base after share buybacks.
Debt-to-equity stood at 43.89 versus 4.14 the year before, and the current ratio was 4.66. At the end of FY 2025, HALO traded at 27.5 times earnings; across the 7 fiscal years shown, its year-end P/E ranged from 13.9 to 46.9, with a median of 27.5. Valuation ratios use the closing share price on each fiscal year-end date and diluted shares from the income statement; profitability and leverage ratios use reported annual figures. Current valuation multiples are on the statistics page.
Summary generated from market data by MetaCap's automated system. Methodology
Halozyme Therapeutics financial ratios (annual)
| Ratio | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| P/E ratio (at fiscal year end) | 27.46 | 13.92 | 17.60 | 39.51 | 14.68 | 46.93 | — | — | 45.02 | — |
| Price / sales | 6.03 | 5.96 | 5.88 | 11.80 | 12.76 | 21.74 | 13.06 | 13.92 | 8.73 | 8.62 |
| Price / book | 172.61 | 16.64 | 58.18 | 45.86 | 28.71 | 38.51 | 27.89 | 8.49 | 13.26 | — |
| Gross margin | 83.6% | 84.3% | 76.8% | 78.9% | 81.6% | 83.8% | 76.8% | 93.3% | 90.2% | 77.4% |
| Operating margin | 33.6% | 54.3% | 40.7% | 40.5% | 62.2% | 53.9% | -34.5% | -45.7% | 25.6% | -56.7% |
| Net margin | 22.7% | 43.7% | 34.0% | 30.6% | 90.8% | 48.2% | -36.9% | -52.9% | 19.9% | -70.2% |
| Free cash flow margin | 46.2% | 46.1% | 45.0% | 35.6% | 67.2% | 19.8% | -45.6% | -35.7% | 41.9% | -36.5% |
| Return on equity (ROE) | 649.2% | 122.1% | 336.0% | 119.0% | 204.5% | 85.5% | -78.7% | -32.3% | 30.2% | — |
| Return on assets (ROA) | 12.5% | 21.5% | 16.2% | 11.0% | 36.5% | 22.3% | -12.8% | -18.2% | 12.1% | -39.4% |
| Debt / equity | 43.89 | 4.14 | 17.89 | 8.87 | 4.45 | 2.63 | 4.39 | 0.51 | 0.97 | — |
| Current ratio | 4.66 | 7.80 | 6.64 | 5.65 | 7.91 | 1.32 | 6.35 | 2.86 | 3.89 | 4.70 |
| Revenue growth | 37.6% | 22.4% | 25.6% | 48.9% | 65.7% | 36.5% | 29.1% | -52.0% | 115.8% | 8.6% |
| EPS growth | -25.4% | 63.3% | 45.8% | -47.4% | 201.1% | — | — | -224.4% | — | — |